Beyond the scale, GLP-1 treatments support heart health, improve insulin sensitivity, and reduce risks linked to obesity
Yesunder the guidance of our medical team, many clients experience significant changes in their appetite, energy, body composition, and relationship with food
The trial was registered on 30 December 2019 at Iranian Registry of Clinical Trials IRCT20191016045131N1
Prevention of muscle loss with dietary approach Given the sarcopenia-related increase in morbidity and mortality, preventing muscle mass loss in patients taking weight-loss drugs, such as GLP-1RAs, is of primary importance and should include both physical exercise and dietary strategies [37]
That was a bit disappointing to see that it did not pan out even with this large trial, he said